UK low-dose CT lung cancer screening study results withheld
This article was originally published in Clinica
Executive Summary
The feasibility study and protocol development for the UK Lung Cancer Screening Trial (UKLS) has been completed, but its findings will not be published for now. The protocol for the trial was to be based on the use of low-dose computed tomography (LDCT). "The findings may form part of a larger report at a later date," explained the NHS' health technology assessment programme, in a project update posted this week. The study, which began in October 2008, was led by Professor John Field, of the Surgery and Oncology School of Cancer Studies, University of Liverpool. The NHS' HTA programme is managed by the NIHR Coordinating Centre for Health Technology Assessment (NCCHTA). Lung cancer kills some 33,500 people in the UK every year.
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.